Merit Medical Systems INC 8-K filings

Merit Medical Systems announced second quarter 2026 financial results exceeding expectations, driven by robust revenue growth and improved margins, leading to an upward revision of full-year guidance.

Merit Medical Systems, Inc. announced shareholder approval of its 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan, alongside director elections and auditor ratification.

Merit Medical reported Q1 2026 revenue of $381.9 million, up 7% year-over-year, and updated its full-year 2026 financial guidance.

Merit Medical Systems provides a detailed historical revenue breakdown by foundational and therapeutic product categories for 2022-2025.

Merit Medical Systems, Inc. announced the acquisition of View Point Medical, Inc. for approximately $140 million, expanding its therapeutic oncology product line with the OneMark Detection Imaging System.

Merit Medical Systems, Inc. reported better-than-expected fourth quarter and full-year 2025 financial results, alongside optimistic guidance for fiscal year 2026.

Merit Medical Systems, Inc. announced the appointment of F. Ann Millner as Chair of the Board following Fred P. Lampropoulos's resignation and reported preliminary unaudited Q4 2025 revenue growth of 10% to 11% year-over-year.

Merit Medical Systems, Inc. announced a strategic pivot for its WRAPSODY Cell-Impermeable Endoprosthesis U.S. commercialization after CMS deferred its TPT incremental payment application.

Merit Medical Systems, Inc. announced the successful closing of its acquisition of the C2 CryoBalloon device and related technology from Pentax of America, Inc.

Merit Medical Systems, Inc. reported better-than-expected third-quarter 2025 financial results and raised its full-year revenue and non-GAAP EPS guidance.

Merit Medical Systems, Inc. has signed a definitive asset purchase agreement to acquire the C2 CryoBalloon device and related technology from Pentax of America, Inc. for $22 million.

Merit Medical Systems, Inc. announced the appointment of Martha G. Aronson as President and CEO, effective October 3, 2025, succeeding Fred P. Lampropoulos.

Merit Medical Systems, Inc. reported better-than-expected second-quarter 2025 financial results, driven by strong revenue growth and improved profitability, leading to an upward revision of its full-year 2025 guidance.

Merit Medical Systems, Inc. announced the appointment of Martha Aronson as its new President and CEO, effective October 3, 2025, alongside preliminary unaudited second-quarter 2025 revenue projected to increase by 12% to 14%.

Merit Medical Systems, Inc. has acquired Biolife Delaware, L.L.C. for $120 million in cash, expanding its hemostasis solutions portfolio.

Merit Medical Systems held its 2025 Annual Meeting of Shareholders on May 14, 2025, with all proposals passing, including the election of directors, approval of executive compensation, and ratification of the appointment of Deloitte & Touche LLP as the independent accounting firm.

Merit Medical Systems announces a 9.8% increase in revenue for Q1 2025 and updates its full-year guidance.

Merit Medical Systems reports a strong finish to 2024 with better-than-expected financial results and issues optimistic guidance for fiscal year 2025.

Merit Medical Systems initiates the U.S. commercial launch of its WRAPSODY Cell-Impermeable Endoprosthesis (CIE) following FDA premarket approval, projecting $7 million to $9 million in revenue for 2025.

Merit Medical Systems reports preliminary unaudited revenue for 2024 in the range of $1.355 billion to $1.357 billion, projecting a year-over-year increase of approximately 7.7% to 7.9%.

Merit Medical Systems' President, Joseph C. Wright, has resigned effective January 3, 2025, following an investigation into allegations regarding his conduct, and CEO Fred P. Lampropoulos has been reappointed as President.

Merit Medical Systems has finalized its acquisition of Cook Medical's lead management portfolio for approximately $210 million in cash and the assumption of certain liabilities.

Merit Medical Systems reported strong third-quarter results, exceeding expectations and raising its full-year financial guidance.

Merit Medical Systems, Inc. has agreed to acquire Cook Medical's lead management portfolio for approximately $210 million, expecting the deal to close in the fourth quarter of 2024 and updating its full-year 2024 financial guidance.

Merit Medical Systems reported better-than-expected second-quarter results, driven by strong revenue growth and improved profitability, leading to an increased full-year financial outlook.

Merit Medical Systems has acquired the EsophyX Z+ device and related assets from EndoGastric Solutions for $105 million, aiming to expand its presence in the gastrointestinal market.

Merit Medical Systems has appointed Silvia M. Perez as a new director, amended its bylaws to clarify executive responsibilities, and increased the number of shares authorized under its incentive plan.

Merit Medical Systems has appointed Joe Wright as President, effective May 15, 2024, as part of its ongoing leadership development and growth initiatives.

Merit Medical reported better-than-expected revenue and earnings for the first quarter of 2024, driven by strong organic growth and improved profitability.

Merit Medical Systems reported a 10.6% increase in revenue for Q4 2023 and introduced a new Continued Growth Initiatives Program with financial targets through 2026.